Biweekly Paclitaxel and Gemcitabine for Patients with Advanced Urothelial Cancer Ineligible for Cisplatin-Based Regimen-Reference-Cited by-同舟云学术

Biweekly Paclitaxel and Gemcitabine for Patients with Advanced Urothelial Cancer Ineligible for Cisplatin-Based Regimen

Published:2006-01-17 Issue:2 Volume:36 Page:104-108
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Takahashi Takeshi,Higashi Shin,Nishiyama Hiroyuki,Segawa Takeshiko,Nakamura Eijiro,Kinoshita Hidefumi,Itoh Noriyuki,Yamamoto Shingo,Kamoto Toshiyuki,Habuchi Tomonori,Ogawa Osamu

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/36/2/104/5085799/hyi220.pdf

Reference19 articles.

1. Lehmann J, Retz M, Stockle M. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy. World J Urol2002;20:144.

2. de Wit R, Bellmunt J. Overview of gemcitabine triplets in metastatic bladder cancer. Crit Rev Oncol Hematol2003;45:191.

3. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol2000;18:3068.

4. Meluch AA, Greco FA, Burris HA III, O'Rourke T, Ortega G, Steis RG, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol2001;19:3018.

5. Rothenberg ML, Sharma A, Weiss GR, Villalona-Calero MA, Eckardt JR, Aylesworth C, et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol1998;9:733.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature;Journal of Urology;2016-02

2. Second-Line Therapies in Metastatic Urothelial Carcinoma;Hematology/Oncology Clinics of North America;2015-04

3. Role of Systemic Chemotherapy in Urothelial Urinary Bladder Cancer;Cancer Control;2013-07

4. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: A phase II study;Asia-Pacific Journal of Clinical Oncology;2012-08-09

5. Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis;Cancer Chemotherapy and Pharmacology;2012-08-03